ly3298176 tirzepatide Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial Tirzepatide cuts heart failure risk
Pay in 4 interest-free payments of $5.93 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27




















:max_bytes(150000):strip_icc()/GettyImages-1299286851-18ab6e02931940ad963dda93851b6dc7.jpg)






